On Tuesday, Vertex saw a notable increase in its stock value, while Maze Therapeutics experienced a significant surge in their shares, due to an unexpected expansion of their kidney disease drug portfolio. This unexpected development caused Vertex's stock to rise, and Maze Therapeutics' shares to skyrocket. The specific figures detailing the increase in stock prices and market capitalization were not disclosed in the report.